SE9501302D0 - Antibodies for use in cancertherapy and diagnosis - Google Patents

Antibodies for use in cancertherapy and diagnosis

Info

Publication number
SE9501302D0
SE9501302D0 SE9501302A SE9501302A SE9501302D0 SE 9501302 D0 SE9501302 D0 SE 9501302D0 SE 9501302 A SE9501302 A SE 9501302A SE 9501302 A SE9501302 A SE 9501302A SE 9501302 D0 SE9501302 D0 SE 9501302D0
Authority
SE
Sweden
Prior art keywords
antibodies
antibody
diagnosis
ext1
cancer
Prior art date
Application number
SE9501302A
Other languages
English (en)
Inventor
Roland Carlsson
Bo Jansson
Original Assignee
Bioinvent Internatioal Ab
Pronova As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Internatioal Ab, Pronova As filed Critical Bioinvent Internatioal Ab
Priority to SE9501302A priority Critical patent/SE9501302D0/sv
Publication of SE9501302D0 publication Critical patent/SE9501302D0/sv
Priority to AU52799/96A priority patent/AU5279996A/en
Priority to PCT/GB1996/000783 priority patent/WO1996031539A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE9501302A 1995-04-07 1995-04-07 Antibodies for use in cancertherapy and diagnosis SE9501302D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9501302A SE9501302D0 (sv) 1995-04-07 1995-04-07 Antibodies for use in cancertherapy and diagnosis
AU52799/96A AU5279996A (en) 1995-04-07 1996-04-01 Antibodies and their use in cancer therapy and diagnosis
PCT/GB1996/000783 WO1996031539A1 (en) 1995-04-07 1996-04-01 Antibodies and their use in cancer therapy and diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501302A SE9501302D0 (sv) 1995-04-07 1995-04-07 Antibodies for use in cancertherapy and diagnosis

Publications (1)

Publication Number Publication Date
SE9501302D0 true SE9501302D0 (sv) 1995-04-07

Family

ID=20397891

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501302A SE9501302D0 (sv) 1995-04-07 1995-04-07 Antibodies for use in cancertherapy and diagnosis

Country Status (3)

Country Link
AU (1) AU5279996A (sv)
SE (1) SE9501302D0 (sv)
WO (1) WO1996031539A1 (sv)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2891666T (pt) 2002-10-16 2017-09-22 Purdue Pharma Lp Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
JPH01211497A (ja) * 1988-02-19 1989-08-24 Aichi Pref Gov ヒトムチン性卵巣腫瘍に対するモノクローナル抗体及び該抗体を用いるヒト卵巣腫瘍の検出法
JP2660241B2 (ja) * 1990-10-12 1997-10-08 アメリカ合衆国 モノクロナール抗体
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
JPH0723400B2 (ja) * 1992-12-07 1995-03-15 愛知県 ヒトムチン性卵巣腫瘍に対するモノクローナル抗体及び該抗体を用いるヒト卵巣腫瘍の検出法

Also Published As

Publication number Publication date
WO1996031539A1 (en) 1996-10-10
AU5279996A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
MY108519A (en) Novel antibodies reactive with human carcinomas.
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
EP1585966B8 (en) Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GB9223377D0 (en) Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1999066951A8 (en) Use of bi-specific antibodies for pre-targeting diagnosis and therapy
RS80704A (en) ANTI- av?6.ANTIBODIES
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
EP2067788A3 (en) Fab fragment libraries and methods for their use
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
ATE375802T1 (de) Ccr5 antikörper pa14
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
NZ501990A (en) Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
SE9501302D0 (sv) Antibodies for use in cancertherapy and diagnosis
WO2004113388A3 (en) Anti alpha - folate - receptor - tetramer antibodies
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
SE9500148D0 (sv) Antibodies for use in cancer therapy and diagnosis
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
WO2022174103A3 (en) Monoclonal antibodies specific for human ror1
ATE76583T1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.